ID: ALA4447985

Max Phase: Preclinical

Molecular Formula: C15H22F3N3O6

Molecular Weight: 283.33

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  NC[C@H]1CC[C@@H](COC(=O)NC2CC(=O)NC2=O)CC1.O=C(O)C(F)(F)F

Standard InChI:  InChI=1S/C13H21N3O4.C2HF3O2/c14-6-8-1-3-9(4-2-8)7-20-13(19)15-10-5-11(17)16-12(10)18;3-2(4,5)1(6)7/h8-10H,1-7,14H2,(H,15,19)(H,16,17,18);(H,6,7)/t8-,9+,10?;

Standard InChI Key:  NBXSSUNRQRBXQD-CVLICLBHSA-N

Associated Targets(Human)

Cereblon/Casein kinase I alpha 35 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cereblon/Aiolos 164 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Cereblon isoform 4 52 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 283.33Molecular Weight (Monoisotopic): 283.1532AlogP: -0.11#Rotatable Bonds: 4
Polar Surface Area: 110.52Molecular Species: BASEHBA: 5HBD: 3
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 4#RO5 Violations (Lipinski): 0
CX Acidic pKa: 9.15CX Basic pKa: 10.26CX LogP: -1.65CX LogD: -3.03
Aromatic Rings: 0Heavy Atoms: 20QED Weighted: 0.62Np Likeness Score: -0.18

References

1. Heim C, Pliatsika D, Mousavizadeh F, Bär K, Hernandez Alvarez B, Giannis A, Hartmann MD..  (2019)  De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives.,  62  (14): [PMID:31251063] [10.1021/acs.jmedchem.9b00454]

Source